A novel colchicine-binding site inhibitor suppresses triple-negative breast cancer growth and metastasis and synergizes with anti-PD-L1 immunotherapy in an immunogenic cancer model
/M arrest and apoptosis and can bypass taxane resistance. SP-1-39, a novel CBSI, exhibits potent anti-cancer activity in a paclitaxel-resistant prostate cancer in vivo model, confirming its capacity to overcome chemoresistance. We also discovered that SP-1-39 upregulates PD-L1 expression in vitro, suggesting synergy with immune checkpoint blockade. This study evaluates the anti-metastatic activity of SP-1-39 in metastatic TNBC and the therapeutic potential of combining SP-1-39 with anti-PD-L1 immune checkpoint inhibition in a PD-L1-responsive colon cancer model. Our findings provide preclinical evidence supporting SP-1-39 as a promising therapeutic agent for TNBC and other solid tumors, either as a single agent or in combination with immunotherapy.
Authors
- Duane D. Miller (ORCID: https://orcid.org/0000-0002-6093-0985)
- Damilola Oluwalana (ORCID: https://orcid.org/0000-0002-6298-9550)
- Gustavo A. Miranda‐Carboni (ORCID: https://orcid.org/0000-0003-1313-9207)
- Raisa I. Krutilina (ORCID: https://orcid.org/0000-0002-2118-4019)
- Kelli L. Adeleye (ORCID: https://orcid.org/0000-0002-8017-7580)
- Satyanarayana Pochampally (ORCID: https://orcid.org/0000-0001-7617-9906)
- Tiffany N. Seagroves (ORCID: https://orcid.org/0000-0002-6937-943X)
- Yang Xie (ORCID: https://orcid.org/0000-0003-0656-5152)
- Lily Waltz (ORCID: https://orcid.org/0000-0003-1884-4204)
- Wei Li (ORCID: https://orcid.org/0000-0002-9522-4474)
Institutions
- Tulane University (US)
- St. Jude Children's Research Hospital (US)
- University of Tennessee Health Science Center (US)
Publication Details
- Journal
- Biomedicine & Pharmacotherapy
- Published
- 2026-04-10
- DOI
- https://doi.org/10.1016/j.biopha.2026.119353
- Primary Topic
- Inflammasome and immune disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Drug Discovery Center, College of Pharmacy, Health Science Center, University of Tennessee
- National Institutes of Health
- National Cancer Institute